Heat Biologics, Inc. (HTBX)

Oncology Corporate Profile

Stock Performance

0.6917
-0.0283

HQ Location

100 Europa Drive, Suite 420
Chapel Hill, NC 27517

Company Description

Heat Biologics, Inc.¥_is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf"¥_ImPACT¥_therapeutic vaccines to combat a wide range of cancers. Their¥_ImPACT¥_Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells.¥_

Website: http://www.heatbio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
vesigenurtucel-L / HS-410cytotoxic t-cell specific adjuvantBladder cancerII
vesigenurtucel-L (+cyclophosphamide) / HS-110cytotoxic t-cell specific adjuvantNon Small Cell Lung Cancer (NSCLC)II
vesigenurtucel-L (+nivolumab) / HS-110cytotoxic t-cell specific adjuvantNon Small Cell Lung Cancer (NSCLC)II

View additional information on product candidates here »

Source


http://www.heatbio.com

Recent News Headlines

Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock

3/23/2017 12:00 pm

[GlobeNewswire] - DURHAM, N.C., March 23, 2017-- HEAT BIOLOGICS, INC., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced the pricing of an underwritten ...

Heat Biologics Announces Proposed Public Offering of Common Stock

3/22/2017 08:00 pm

[GlobeNewswire] - DURHAM, N.C., March 22, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that it intends to offer for ...

Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor

3/21/2017 11:00 am

[GlobeNewswire] - ELISPOT results suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients. Tumor reduction corresponds to enhanced immune response. ...

Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

3/20/2017 11:00 am

[Accesswire] - DURHAM, NC / ACCESSWIRE / March 20, 2017 / Heat Biologics, Inc. ( NASDAQ: HTBX , "Heat"), a leader in the development of immunotherapies designed to activate a patient's immune system against ...

Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine

3/16/2017 11:00 am

[GlobeNewswire] - Natasa Strbo’ s Zika preclinical research at the University of Miami DURHAM, N.C., March 16, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ ...

Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2

3/13/2017 11:00 am

[GlobeNewswire] - Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’ s anti-PD-1 checkpoint inhibitor, nivolumab. Signs of synergistic efficacy with nivolumab enables expansion to a Phase 2 ...

Blog Coverage Heat Biologics Acquires Controlling Stake in Immuno-Oncology Company Pelican Therapeutics

3/9/2017 01:01 pm

[Accesswire] - Upcoming AWS Coverage on AveXis Post-Earnings Results LONDON, UK / ACCESSWIRE / March 9, 2017 / Active Wall St. blog coverage looks at the headline from Heat Biologics, Inc. (NASDAQ: HTBX ) ("Heat") ...

Heat Biologics to Present at 29th Annual ROTH Conference

3/9/2017 01:00 pm

[GlobeNewswire] - DURHAM, N.C., March 09, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that Jeff Wolf, Heat’ s Founder ...

Heat Biologics Announces Agreement to Acquire Pelican Therapeutics

3/8/2017 12:00 pm

[GlobeNewswire] - Acquisition brings $15.2 million CPRIT grant to fund 70- patient Phase I trial. DURHAM, N.C., March 08, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate ...

Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting

3/2/2017 01:00 pm

[GlobeNewswire] - DURHAM, N.C., March 02, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that it will present a poster ...

Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium

2/17/2017 12:00 pm

[GlobeNewswire] - DURHAM, N.C., Feb. 17, 2017-- Heat Biologics, Inc., announced that it presented a poster of its immunological data from its 94- patient Phase 2 trial evaluating vesigenurtacel-L either alone or in combination ...

Heat Biologics to Present at the Genitourinary Cancers Symposium

2/14/2017 01:00 pm

[GlobeNewswire] - DURHAM, N.C., Feb. 14, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that it will present a poster ...